Quick answers
- What is Lidocaine and tetracaine used for?
- The FDA-approved label (Pliaglis, Ipg Pharmaceuticals, Inc., March 9, 2026) says: “PLIAGLIS is indicated for use on intact skin in adults to provide topical local analgesia for superficial dermatological procedures such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Lidocaine and tetracaine have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Lidocaine and tetracaine?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Lidocaine and tetracaine been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Lidocaine and tetracaine?
- 1 company lists prescription products of Lidocaine and tetracaine in the FDA NDC Directory, including IPG Pharmaceuticals, Inc..
What Lidocaine and tetracaine is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
PLIAGLIS is indicated for use on intact skin in adults to provide topical local analgesia for superficial dermatological procedures such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal. …
— FDA label: Pliaglis, Ipg Pharmaceuticals, Inc., effective March 9, 2026. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Forms and how it is given
| Dosage forms | Cream |
|---|---|
| Route | Topical |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Pliaglis |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- IPG Pharmaceuticals, Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021717 PLIAGLIS | Crescita Therap | June 29, 2006 | 6, latest December 11, 2018 2018: Labeling · 2018: Labeling · 2017: Labeling |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 687443, 728126 |
|---|---|
| SPL set ID of the quoted label | d854faa5-0af8-4684-b5cd-a0b8a91fb7cd |
| FDA labels (SPL) | 1 |
| FDA applications | NDA021717 |
| Active ingredients (FDA) | LIDOCAINE / TETRACAINE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Pliaglis, Ipg Pharmaceuticals, Inc., effective March 9, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →